Latest stories on MTVA
MetaVia Advances DA-1726 Obesity Trial to Top Doses
TipRanks63 · neutralproduct/pr
MetaVia Inc. (MTVA) files 8-K
SEC 8-K50 · neutralgeneral
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity | MTVA Stock News
StockTitan67 · bullishproduct/pr
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
PR Newswire59 · neutralproduct/pr
MetaVia Announces $4 Million At-The-Market Stock Offering
TipRanks24 · bearishgeneral
MetaVia Inc. (MTVA) files 8-K
SEC 8-K50 · neutralgeneral
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum | MTVA Stock News
StockTitan56 · neutralproduct/pr
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
PR Newswire56 · neutralproduct/pr
MetaVia highlights obesity and metabolic pipeline advancements
TipRanks63 · neutralproduct/pr
MetaVia Inc. (MTVA) files 8-K
SEC 8-K50 · neutralgeneral
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference | MTVA Stock News
StockTitan56 · neutralproduct/pr
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
PR Newswire56 · neutralproduct/pr
MetaVia highlights promising Phase 1 obesity drug data
TipRanks73 · bullishproduct/pr
3 Penny Stocks to Watch Now, 5/21/26
TipRanks57 · neutralgeneral
Peer-Reviewed Evidence Highlights Vanoglipel’s Promise in Tackling Liver Fibrosis and MASH
MarketChameleon67 · bullishproduct/pr
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
PR Newswire63 · neutralproduct/pr
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
PR Newswire63 · neutralproduct/pr
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire63 · neutralearnings